Clinical trial · Interventional
Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Primitive Neuroectodermal Tumors
Treatment of High Risk Central Nervous System Embryonal Tumors With Conventional Radiotherapy and Intensive Consolidation Chemotherapy With Peripheral Blood Progenitor Cell (PBSC) Support
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Radiation therapy uses x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of radiation therapy and chemotherapy and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of radiation therapy, chemotherapy and peripheral stem cell transplantation in treating patients with primitive neuroectodermal tumors.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain and Central Nervous System Tumors | Central Nervous System Neoplasm | PROBABILISTIC | 0.70 |
| Neuroblastoma | Neuroblastoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (8)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| bone marrow ablation with stem cell support | Procedure | — | UNRESOLVED |
| carboplatin | Drug | Carboplatin | ALIAS |
| cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| filgrastim | Biological | Filgrastim | ALIAS |
| peripheral blood stem cell transplantation | Procedure | — | UNRESOLVED |
| radiation therapy | Radiation | — | UNRESOLVED |
| thiotepa | Drug | Thiotepa | ALIAS |
| vincristine sulfate | Drug | Vincristine | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Treatment
- description
- See detailed description.
- interventionNames
- Biological: filgrastim
- Drug: carboplatin
- Drug: cyclophosphamide
- Drug: thiotepa
- Drug: vincristine sulfate
- Procedure: bone marrow ablation with stem cell support
- Procedure: peripheral blood stem cell transplantation
- Radiation: radiation therapy
Primary outcomes (1)
- measure
- Event Free Survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 3 Years
- Maximum age
- 21 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically proven primitive neuroectodermal tumor (PNET) of one of the following types: * Atypical teratoid/rhabdoid tumor * Medulloblastoma * Desmoplastic medulloblastoma * Ependymoblastoma * Medullomyoblastoma * Spongioblastoma * Spongioblastoma polare * Primitive polar spongioblastoma * Medulloepithelioma * Neuroblastoma * Pineoblastoma * Posterior fossa PNET must be M1-3 or M0 with greater than 1.5 cm2 residual disease * Non posterior fossa PNET and other types must be M0-3 * If M3, must show clear evidence of tumor on MRI * No marrow involvement or other extraneural metastases * No M4 disease * No cord compression requiring emergency radiotherapy PATIENT CHARACTERISTICS: Age: * 3 to 21 Performance status: * Not specified Life expectancy: * Not specified Hematopoietic: * Absolute neutrophil count at least 1,000/mm\^3 * Platelet count at least 150,000/mm\^3 (no platelet transfusions) * Hemoglobin at least 10 g/dL (red blood cell transfusions allowed) Hepatic: * Bilirubin less than 1.5 times upper limit of normal (ULN) * AST or ALT less than 2.5 times ULN Renal: * Creatinine clearance or glomerular filtration rate at least 70 mL/min Cardiovascular: * Shortening fraction greater than 27% by echocardiogram OR * Ejection fraction greater than 47% by MUGA Pulmonary: * FEV\_1/FVC greater than 60% except for children who: * Are uncooperative * Have no dyspnea at rest * Have no exercise intolerance * Have pulse oximetry greater than 94% on room air Other: * Not pregnant or nursing PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * Not specified Endocrine therapy: * Steroids for increased intracranial pressure allowed Radiotherapy: * See Disease Characteristics * No prior urgent radiotherapy Surgery: * Not specified Other: * No prior therapy for tumor
References
Publications (0)
Data not yet available